Abstract
Renal cell carcinoma (RCC) represents approximately 3% of all adult cancers and is more common in males. Systemic treatment for RCC has improved following the introduction of sunitinib. Bone metastases are present in up to 50% of RCC patients. We report a case of rapid improvement in metastatic bone lesions, recorded by nuclear bone scan, in a male patient receiving localized palliative radiotherapy in addition to systemic sunitinib and zoledronic acid. Concurrently, quality of life and performance status improved dramatically. Although we are unsure of the exact mechanism for such rapid improvement in metastatic bone lesions, the swiftness this improvement deserves reporting.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antineoplastic Agents / administration & dosage
-
Bone Density Conservation Agents / administration & dosage
-
Bone Neoplasms / drug therapy
-
Bone Neoplasms / radiotherapy
-
Bone Neoplasms / secondary
-
Carcinoma, Renal Cell / pathology
-
Carcinoma, Renal Cell / therapy*
-
Combined Modality Therapy
-
Diphosphonates / administration & dosage
-
Humans
-
Imidazoles / administration & dosage
-
Indoles / administration & dosage
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / therapy*
-
Male
-
Nephrectomy
-
Pain Management*
-
Palliative Care / methods*
-
Pyrroles / administration & dosage
-
Quality of Life
-
Sunitinib
-
Zoledronic Acid
Substances
-
Antineoplastic Agents
-
Bone Density Conservation Agents
-
Diphosphonates
-
Imidazoles
-
Indoles
-
Pyrroles
-
Zoledronic Acid
-
Sunitinib